Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27238513
Abstract: BRAF is a serine/threonine kinase frequently mutated in human cancers. BRAFV600E mutated protein is targeted through the use of kinase inhibitors which are approved for the treatment of melanoma; however, their long-term efficacy is hampered… read more here.
Keywords: investigation use; encorafenib develop; use encorafenib; kinase ... See more keywords